Te Ara Waiora–Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280643 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS ONE, 2023. Verfasst von Melanie Gibson-Helm und 16 weiteren Autor:innen. Beteiligte Einrichtung: Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Ministry of Health, New Zealand, Mahitahi Hauora, Primary Health Entity.
Abstract (Originalsprache)
Background
Cervical cancer is caused by high-risk types of human papillomavirus (HPV). Testing for high-risk HPV is a more sensitive screening method than cervical cytology for detecting cervical changes that may lead to cancer. Consistent with recent evidence of efficacy and acceptability, Aotearoa New Zealand plans to introduce HPV testing as the primary approach to screening, replacing cervical cytology, from mid-2023. Any equitable cervical screening programme must be effective across a diverse population, including women that the current programme fails to reach, particularly Māori and those in rural areas. Currently, we do not know the best model for implementing an equitable HPV self-testing screening programme.
Methods
This implementation trial aims to assess whether a universal offer of HPV self-testing (offered to all people eligible for cervical screening) achieves non-inferior screening coverage (equal) to a universal offer of cervical cytology alone (the present programme). The study population is all people aged from 24.5 to 70 years due for cervical screening in a 12-month period (including those whose screening is overdue or who have never had screening). A range of quantitative and qualitative secondary outcomes will be explored, including barriers and facilitators across screening and diagnostic pathways. This study takes place in Te Tai Tokerau/Northland which covers a diverse range of urban and rural areas and has a large Indigenous Māori population. A total of fourteen practices will be involved. Seven practices will offer HPV self-testing universally to approximately 2800 women and will be compared to seven practices providing routine clinical care (offer of cervical cytology) to an approximately equal number of women.
Discussion
This trial will answer important questions about how to implement an equitable, high-quality, effective national programme offering HPV self-testing as the primary screening method for cervical cancer prevention.
Trial registration
Prospectively registered with the Australian New Zealand Clinical Trials Registry 07/12/2021: ACTRN12621001675819 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Te Tātai Hauora o Hine-National Centre for Women's Health Research Aotearoa (NCWHRA), Victoria University of Wellington, Wellington, New Zealand.
- National Center of Excellence in Women's Health, University of Illinois, Chicago, IL, United States of America.
- National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.
- Department of Pathology, University of Otago, Dunedin, New Zealand.
- Christchurch Hospital and University of Otago, Canterbury, New Zealand.
- Australian Centre for the Prevention of Cervical Cancer, Melbourne, Australia.
Förderung
- Health Research Council of New Zealand
- Ministry of Health, New Zealand
- Mahitahi Hauora, Primary Health Entity
Zitieren
APA
Gibson-Helm, M., Slater, T., MacDonald, E. J., Stevenson, K., Adcock, A., Geller, S., Parag, V., Lambert, C., Bennett, M., Hibma, M., Sykes, P., Saville, M., Hawkes, D., Stanton, J. A., Clueard, M. A., Jelley, G., & Lawton, B. (2023). Te Ara Waiora–Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0280643
Vancouver
Gibson-Helm M, Slater T, MacDonald EJ, Stevenson K, Adcock A, Geller S, et al. Te Ara Waiora–Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial. PLOS ONE. 2023. doi:10.1371/journal.pone.0280643
BibTeX
@article{GibsonHelm2023,
author = {Gibson-Helm, Melanie and Slater, Tania and MacDonald, Evelyn J and Stevenson, Kendall and Adcock, Anna and Geller, Stacie and Parag, Varsha and Lambert, Charles and Bennett, Matthew and Hibma, Merilyn and Sykes, Peter and Saville, Marion and Hawkes, David and Stanton, Jo-Ann and Clueard, Mary-Ann and Jelley, Grahame and Lawton, Bev},
title = {Te Ara Waiora–Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280643}
}
EUVIMED